LadRx Corp (LADXD)

[ice1234]

(CYTR a biopharmaceutical research and development company specializing in oncology, today highlighted that aldoxorubicin licensee NantCell, Inc., a private subsidiary of NantWorks, LLC, has informed the Company that it plans to submit Investigational New Drug (IND) applications combining aldoxorubicin with its immunotherapy protocols for clinical trials addressing patients diagnosed with Pancreatic and Breast cancer.

The planned clinical trials will enroll patients with cancers that are no longer responding, or never responded, to standard therapy and have progressed. The clinical trials will employ an adaptive design which will allow for expansion of treatment cohorts and modification of patient treatments based on tumor profiling and individual patient responses over time.

"The inclusion of aldoxorubicin in NantCell's upcoming pending IND filings is important validation of its potential ability to provide benefit for patients with advanced-stage, difficult to treat cancers," commented Steven A. Kriegsman, CytRx's Chairman and Chief Executive Officer. "These planned trials allow for the continued development of aldoxorubicin in patient populations with great needs for transformation in cancer care."


https://ih.advfn.com/p.php?pid=nmona&article=75849080